Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $58.6, along ...

Arcturus Therapeutics, based in San Diego, has proprietary enabling technologies: (i) LUNAR lipid-mediated delivery, (ii) self-transcribing and replicating mRNA (STARR) technology, and (iii ...

Arcturus Therapeutics Holdings Inc is an RNA ... This article was generated by Benzinga's automated content engine and reviewed by an editor.

Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant ...

HC Wainwright reaffirmed a “buy” rating and issued a $63.00 price objective on shares of Arcturus Therapeutics in a research note on Monday, January 13th. Cantor Fitzgerald reiterated an ...

Across the recent three months, 5 analysts have shared their insights on Arcturus Therapeutics (NASDAQ:ARCT), expressing a variety of opinions spanning from bullish to bearish. The table below ...

Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on Arcturus Therapeutics (NASDAQ:ARCT) in the last three months. The table below summarizes ...